Results 61 to 70 of about 4,498 (182)

Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy

HIV/AIDS: Research and Palliative Care, 2015
Nils von Hentig HIV Center, Medical Department II, Hospital of the JW Goethe-University, Frankfurt, BAG Darab-Kaboly/von Hentig, General Medicine and HIV Care, Frankfurt am Main, Germany Abstract: The pharmacoenhancement of plasma concentrations of ...
von Hentig N
doaj  

Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir

Antiviral Therapy
Background Integrase strand transfer inhibitors (INSTIs) have been associated with excess weight gain in people living with HIV compared to other antiretroviral agents. The mechanisms that underlie these effects are not well defined.
Richard Taylor Pickering, Archana Asundi, Alex Olson, Katie Soden, Daniel R Kuritzkes, Nina H Lin   +5 more
doaj   +1 more source

Delayed Clearance of Viral RNA in Sputum for Severity COVID-19 Patients with Initial High Viral Load

Infection and Drug Resistance, 2022
Hong Zhao,* Huilan Tu,* Xia Yu,* Junwei Su, Xuan Zhang, Kaijin Xu, Yu Shi, Yunqing Qiu, Jifang Sheng State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National ...
Zhao H, Tu H, Yu X, Su J, Zhang X, Xu K, Shi Y, Qiu Y, Sheng J   +8 more
doaj  

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

AIDS Research and Therapy, 2019
Background Study aim was to evaluate the safety and durability of darunavir/cobicistat (DRV/c) in a real life setting. Methods Multicentre prospective cohort study performed in the context of SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals)
Lucia Taramasso, Elena Ricci, Antonio Cascio, Laura Valsecchi, Barbara Menzaghi, Nicola Squillace, Paolo Maggi, Giuseppe Vittorio De Socio, Chiara Dentone, Giordano Madeddu, Giovanni F. Pellicanò, Leonardo Calza, Goffredo Angioni, Paolo Bonfanti, Antonio Di Biagio, CISAI Study Group   +15 more
doaj   +1 more source

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 583-586, March 2026.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials

HIV Research & Clinical Practice, 2019
Background: The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naive and ART-experienced Asian ...
Yeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, Amanda Clarke, Khuanchai Supparatpinyo, Anchalee Avihingsanon, Winai Ratanasuwan, Sasisopin Kiertiburanakul, Kiat Ruxrungtham, SangYoun Yang, Susan Guo, YaPei Liu, Moupali Das, Do Tran, Damian McColl, Roberto Corales, Chris Nguyen, David Piontkowsky   +17 more
doaj   +1 more source

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pulmonary Circulation, 2019
Riociguat, a first-in-class soluble guanylate cyclase stimulator, is approved for the treatment of pulmonary arterial hypertension (PAH), a serious potential complication of human immunodeficiency virus (HIV) infection. This open-label study investigated
Edwin DeJesus, Soundos Saleh, Sue Cheng, Dorina van der Mey, Corina Becker, Reiner Frey, Sigrun Unger, Wolfgang Mueck   +7 more
doaj   +1 more source

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source

Pharmacokinetic interaction between single and multiple doses of darunavir, in combination with cobicistat or ritonavir, and single-dose dabigatran etexilate in healthy adults

AAPS Open
Objective Darunavir (DRV) is a P-glycoprotein (P-gp) inhibitor. Dabigatran etexilate, prodrug of the anticoagulant dabigatran, is a P-gp probe substrate. This study evaluated the effect of single and multiple doses of DRV, coadministered with cobicistat (
Sandy Van Hemelryck, Erika Van Landuyt, Jay Ariyawansa, Martyn Palmer, Martine J. C. Kothe, Caroline Pollefliet   +5 more
doaj   +1 more source

Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B)

Contemporary Clinical Trials Communications
Background: Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of the anticancer drug olaparib, a CYP3A-substrate, has the potential to reduce PK variability, side effects and ...
Joanneke K. Overbeek, Niels A.D. Guchelaar, Ma Ida Mohmaed Ali, Muriëlle Sark, Carolien Hovenier, Wietske Kievit, Marjolijn J.L. Ligtenberg, Petronella B. Ottevanger, Haiko J. Bloemendal, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ingrid A. Boere, Alwin D.R. Huitema, Gabe S. Sonke, Frans L. Opdam, Rob ter Heine, Nielka P. van Erp   +16 more
doaj   +1 more source